ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
EIKCS 2022: Debate about later-line treatments
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
Sunitinib as a second-line treatment for advanced kidney cancer after combination immunotherapy
The results from a recent phase 2 trial looked at [...]
Immunotherapy after progression of metastatic kidney cancer
Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) are [...]
EIKCS 2021: Second-line and later treatments for metastatic kidney cancer
The increase in the number of first-line treatments for metastatic [...]
Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer
There is very little information on the effectiveness of sunitinib [...]
Individualising first line treatment for advanced kidney cancer
In recent years, a number of new, effective treatments have [...]
Cabozantinib after immunotherapy in advanced kidney cancer
This recent retrospective study included 84 patients with metastatic renal [...]
New targeted therapy shows potential for previously treated metastatic kidney cancer
A phase II study published in Frontiers in Oncology last [...]
ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer
Results from a phase II trial of a combination of [...]
